Analysis of patients with triple negative breast cancer demonstrated significant response rates and longer progression free survival from the combination of bevacizumab with second-line chemotherapy.

Cooperative group researchers presented their findings at the ASCO annual meeting in Chicago.

Watch Adam Brufsky, MD, PhD, co-director,  Breast Cancer Program and associate director of clinical investigation, UPCI, and professor of medicine, University of Pittsburgh School of Medicine, discuss the oral presentation: